Porownywarka

Pentadecapeptide vs BPC-157 side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

PentadecapeptideBPC-157

Udostępnij porównanie peptydów

Wlasciwosc	Pentadecapeptide	BPC-157
Kategoria	Regeneracja	Regeneracja
Znany tez jako	BPC-157 Full Sequence, Stable Gastric Pentadecapeptide	Body Protection Compound-157, Pentadecapeptide BPC 157
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Preclinical; same research base as BPC-157. FDA Category 2 with pending reclassification context noted by the source. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Phase 2 recruiting (NCT07437547); investigational. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Tissue healing, gut health, injury recovery	Injury recovery, gut healing, joint and tendon repair
Jak dziala	Pentadecapeptide is described as BPC-157, and its mechanism remains provisional. The supplied evidence emphasizes preclinical findings suggesting effects on angiogenesis, VEGFR2-associated pathways, nitric oxide signaling, and rodent dopaminergic, serotonergic, and adrenergic systems. The source also notes that no single clean receptor mechanism has been confirmed in humans.	The supplied source describes several proposed pathways: VEGFR2-linked angiogenesis, nitric-oxide signaling involving Akt-eNOS, anti-inflammatory effects, and growth-factor signaling. It frames these as predominantly rodent findings and reports that the precise molecular target remains unresolved. These mechanistic claims require corroboration.
Typowe dawkowanie	Limited community data available · See research protocols	250-500 mcg twice daily · 1-2x daily
Dawkowanie z badań	250-500 mcg twice daily · Twice daily · 4-12 weeks typical · Subcutaneous injection	250-500 mcg twice daily · 4-12 weeks in most research protocols · Subcutaneous injection near injury site, or systemic
Typowy czas trwania	4-12 weeks typical	4-12 weeks in most research protocols
Podanie	Subcutaneous injection	Subcutaneous injection near injury site, or systemic
Timing	Morning and evening; sometimes aligned with injury-related activity timing With or without food	Morning and evening (or near injury site timing) With or without food
Poziom dowodów	Przedkliniczne	Badania kliniczne
Mozliwe skutki uboczne	Generally well tolerated (Reported by the source, but not established through completed human clinical trials in the supplied evidence.) Nausea (Reported side effect in the source.) Dizziness (Reported side effect in the source.) +1 więcej Possible histamine release (The source advises caution for MCAS or histamine sensitivity.)	Generally well-tolerated in preclinical studies (Source-reported preclinical characterization; it does not establish human safety.) Nausea (Listed by the source without frequency or causality information.) Dizziness (Listed by the source without frequency or causality information.) +6 więcej Injection site reactions (Listed by the source without frequency or causality information.) Fatigue (Listed by the source without frequency or causality information.) Headache (Listed by the source without frequency or causality information.) May trigger histamine release - use caution with MCAS or histamine sensitivity (Source-reported sensitivity concern; human risk was not quantified.) Potential concern for tumor promotion (angiogenesis) (Source-reported theoretical concern, not an established clinical outcome.) Limited long-term human safety data (The source itself notes limited long-term human safety information.)
Podsumowanie researchu	The supplied source describes a sizeable preclinical literature for BPC-157/Pentadecapeptide, including rodent and laboratory work on tendon, ligament, muscle, bone, and gastrointestinal models. It specifically notes a 2011 Journal of Applied Physiology tendon-cell study reporting increased outgrowth, survival, and migration. The same source cautions that recent reviews report no approved formulation, no validated human dose, and no completed Phase II trial, so human benefit claims remain extrapolations from non-human data. The source also notes WADA prohibition.	According to the supplied account of a 2025 Biomedicines narrative review, the record includes hundreds of animal studies across tendon, muscle, bone, gastrointestinal, liver, and nervous-system models, but only three human pilot reports: knee-pain injection, bladder injection for interstitial cystitis, and intravenous safety. The same account reports no completed randomized controlled human trials and no regulatory approval. It further describes rapid breakdown into amino-acid fragments and a sub-30 minute elimination half-life after injection in rats and dogs, leaving oral delivery uncertain. These claims require independent corroboration.
Referencje	Źródło Źródło +3 więcej Źródło Źródło Źródło	Źródło Źródło +2 więcej Źródło Źródło
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Pentadecapeptide

BPC-157

Kategoria

Regeneracja

Znany tez jako

BPC-157 Full Sequence, Stable Gastric Pentadecapeptide

Body Protection Compound-157, Pentadecapeptide BPC 157

Zatwierdzony przez FDA

Nie

Status kliniczny

Preclinical; same research base as BPC-157. FDA Category 2 with pending reclassification context noted by the source.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Phase 2 recruiting (NCT07437547); investigational.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Tissue healing, gut health, injury recovery

Injury recovery, gut healing, joint and tendon repair

Jak dziala

Pentadecapeptide is described as BPC-157, and its mechanism remains provisional. The supplied evidence emphasizes preclinical findings suggesting effects on angiogenesis, VEGFR2-associated pathways, nitric oxide signaling, and rodent dopaminergic, serotonergic, and adrenergic systems. The source also notes that no single clean receptor mechanism has been confirmed in humans.

The supplied source describes several proposed pathways: VEGFR2-linked angiogenesis, nitric-oxide signaling involving Akt-eNOS, anti-inflammatory effects, and growth-factor signaling. It frames these as predominantly rodent findings and reports that the precise molecular target remains unresolved. These mechanistic claims require corroboration.

Typowe dawkowanie

Limited community data available · See research protocols

250-500 mcg twice daily · 1-2x daily

Dawkowanie z badań

250-500 mcg twice daily · Twice daily · 4-12 weeks typical · Subcutaneous injection

250-500 mcg twice daily · 4-12 weeks in most research protocols · Subcutaneous injection near injury site, or systemic

Typowy czas trwania

4-12 weeks typical

4-12 weeks in most research protocols

Podanie

Subcutaneous injection

Subcutaneous injection near injury site, or systemic

Timing

Morning and evening; sometimes aligned with injury-related activity timing

With or without food

Morning and evening (or near injury site timing)

With or without food

Poziom dowodów

Przedkliniczne

Badania kliniczne

Mozliwe skutki uboczne

Generally well tolerated (Reported by the source, but not established through completed human clinical trials in the supplied evidence.)
Nausea (Reported side effect in the source.)
Dizziness (Reported side effect in the source.)

+1 więcej

Possible histamine release (The source advises caution for MCAS or histamine sensitivity.)

Generally well-tolerated in preclinical studies (Source-reported preclinical characterization; it does not establish human safety.)
Nausea (Listed by the source without frequency or causality information.)
Dizziness (Listed by the source without frequency or causality information.)

+6 więcej

Injection site reactions (Listed by the source without frequency or causality information.)
Fatigue (Listed by the source without frequency or causality information.)
Headache (Listed by the source without frequency or causality information.)
May trigger histamine release - use caution with MCAS or histamine sensitivity (Source-reported sensitivity concern; human risk was not quantified.)
Potential concern for tumor promotion (angiogenesis) (Source-reported theoretical concern, not an established clinical outcome.)
Limited long-term human safety data (The source itself notes limited long-term human safety information.)

Podsumowanie researchu

The supplied source describes a sizeable preclinical literature for BPC-157/Pentadecapeptide, including rodent and laboratory work on tendon, ligament, muscle, bone, and gastrointestinal models. It specifically notes a 2011 Journal of Applied Physiology tendon-cell study reporting increased outgrowth, survival, and migration. The same source cautions that recent reviews report no approved formulation, no validated human dose, and no completed Phase II trial, so human benefit claims remain extrapolations from non-human data. The source also notes WADA prohibition.

According to the supplied account of a 2025 Biomedicines narrative review, the record includes hundreds of animal studies across tendon, muscle, bone, gastrointestinal, liver, and nervous-system models, but only three human pilot reports: knee-pain injection, bladder injection for interstitial cystitis, and intravenous safety. The same account reports no completed randomized controlled human trials and no regulatory approval. It further describes rapid breakdown into amino-acid fragments and a sub-30 minute elimination half-life after injection in rats and dogs, leaving oral delivery uncertain. These claims require independent corroboration.

Referencje

+3 więcej

+2 więcej

Pełny profil